Basel Medical Group Ltd (BMGL)

Basel Medical Group Ltd operates in the healthcare services industry in Singapore, providing specialist orthopedic, trauma, sports medicine and neurosurgical services, health screening and general practice through its clinics. The healthcare business is highly competitive, and competition among healthcare providers for patients has intensified in recent years, with competitors including government-owned hospitals, private hospitals, medical centers and clinics, some of which have longer operating histories, are more established and have greater financial, personnel and other resources. The Group's operations currently only cover Singapore, where it has registered one trademark. The private healthcare sector in Singapore faces structural forces including the Ministry of Health's Fee Benchmarks for private sector professional fees published in November 2018, a trend towards increasing the number of medical practitioners in Singapore, and the advancement of disruptive technology such as telemedicine and e-prescription platforms that offer alternative means for patients to access medical services and medicine.

The Group competes with other government-owned hospitals, private hospitals, medical centers and clinics, as well as any future healthcare business operators. Some competitors may have longer operating histories, be more established and have greater financial, personnel and other resources, and may price their services lower, exerting pricing pressures. Competitors include medical facilities owned or managed by government agencies and trusts, which may have access to wider financing options or may be in a better commercial position to negotiate for the purchase of inventory on more favorable terms than private healthcare providers owned and managed by for-profit interests such as the Group. The Group's success depends on its ability to compete effectively, and its business relies to some extent on the recognition of its brand names and trademarks as well as the reputation of its specialist doctors. The Group's specialist orthopedic, trauma, sports medicine and neurosurgical business, health screening and general practice is spearheaded by its key medical practitioners, who are all medical professionals with extensive experience in their respective subspecialties.

The Group generates revenue primarily through the provision of medical services, with revenue recognized at a point in time as services are transferred. The Group's revenue is derived from medical services provided to individual patients, corporate clients and government clients, with corporate clients tending to incur larger transaction volumes compared to individual patients. The Group is dependent on a number of key relationships with corporations with whom it has entered into arrangements for a significant portion of its patient volume, and anticipates that a number of these key relationships will continue to account for a significant portion of patient volume for the foreseeable future. The Group's clinics are located in private hospitals, medical centers, offices and malls in Singapore, and certain clinics are located in Gleneagles Medical Centre, with which the Group has no direct lease or other agreements but utilizes facilities such as X-Ray facilities or operating suites as and when the need arises.

The Group's medical services segment encompasses specialist orthopedic, trauma, sports medicine and neurosurgical services, health screening and general practice. The Group operates through a network of clinics under various brand names including Singapore Sports & Orthopaedic Clinic, Singapore Knee, Sports and Orthopaedic Clinic, SSOC, Bethesda Medical, Oasis Medical Clinic, Pharma Avenue and Eyetrust Medical. The Group's clinics include locations at Gleneagles Medical Centre, SSOC Orchard, SSOC Farrer Park, SSOC Novena, and Bethesda Medical clinics at Suntec, Grantral Mall Macpherson, Toa Payoh, Beach Road, Margaret Drive and Tampines. The Group's services are priced within the Ministry of Health's Fee Benchmarks, which establish a fee range for each procedure considering factors such as the complexity of medical procedures and the time, effort, and expertise involved.

During the fiscal year ended June 30, 2026, the Group completed the acquisition of Bethesda Medical Pte. Ltd. effective April 30, 2025, with the acquisition accounting reflecting a business combination. The Group effected a 1-for-12 reverse share split on June 22, 2026, resulting in 1,582,111 ordinary shares outstanding as of June 30, 2026. On October 7, 2026, the Group issued and sold 6,000,000 units at a public offering price of US$1.33 per unit, each unit consisting of one Ordinary Share (or one pre-funded warrant to purchase one Ordinary Share) and one common warrant to purchase one Ordinary Share, with each common warrant exercisable immediately at an exercise price equal to 110% of the public offering price per unit and expiring five years from issuance. Immediately after the October 2026 Offering, the Group had 7,582,111 Ordinary Shares issued and outstanding. The Group completed its initial public offering in February 2025, with an over-allotment option exercised in March 2025.

The Group's financial performance reflects its position as an emerging growth company with less than US$1.235 billion in net revenues for its last financial year. The Group has entered into certain loan agreements with certain banks to fund working capital requirements, and has in the past defaulted on certain terms stipulated under such loan agreements. The Group's borrowings include term loans, lease liabilities, short-term borrowings and bank overdrafts. The Group maintains both digital and paper medical records and utilizes physical servers and cybersecurity software, and may implement more robust cybersecurity measures in the future such as intrusion detection systems and encryption of sensitive patient information. For the financial years ended June 30, 2025, and 2026, and for the period from July 1, 2026 up to the latest practicable date prior to the report, the Group has not encountered any breaches, human errors, or similar events that have created an adverse cybersecurity event.

The Group's growth strategy centers on expanding its clinic network and service offerings in Singapore. The Group completed the acquisition of Bethesda Medical Pte. Ltd. effective April 30, 2025, adding multiple clinic locations including Bethesda Medical Clinic Suntec, Bethesda Medical Clinic Grantral Mall Macpherson, Bethesda Medical Clinic Toa Payoh, Bethesda Medical Clinic Beach Road, Bethesda Medical Clinic Margaret Drive and Bethesda Medical Clinic Tampines. The Group's continued expansion may be hampered if it is unable to employ sufficiently skilled and qualified medical practitioners to support its operations, and it is crucial for the Group to recruit and retain sufficiently skilled and qualified medical practitioners as it relies on their professional judgement in providing consistent and standardized experience and services to patients.

The Group may expand its operations to other countries in which it does not currently operate, and will continue to seek the appropriate licenses, approvals and permits in the event of such expansion. The Group may also expand to other cities where it does not possess the same level of familiarity with the regulations and business climate, and there can be no assurance that it will be able to obtain the requisite licenses, approvals and permits in those cities. The regional countries are in a state of rapid political, economic and social changes, which will entail risks to the Group's business and operations if it expands in the region in the future. The Group's ability to adapt to local conditions, regulations and business practices and customs in the future cannot be assured.

The Group faces margin pressure from potential increases in operating costs, namely lease rental rates and risk of relocation. The Group leases the premises of its existing clinics, with present lease terms for most clinics for a period of three years or less. Upon expiry of the leased tenure, landlords have the right to review and revise the terms and conditions of the lease agreements, and the Group faces the possibility of an increase in rent or not being able to renew leases on favorable terms. Any increase in rent would inevitably increase operating costs, thereby affecting profits, and the Group will also incur additional costs if it has to relocate clinics. The Group also faces potential reduction in fees if the Fee Benchmarks are lowered, and heightened competition within the private healthcare sector is likely to put pressure on service rates.

The Group's operational outlook includes reliance on external medical practitioners and vendors, and at times it may enlist locum doctors to support operations. The Group also relies on external vendors and service providers who second radiologists for patients. Certain licenses upon which the Group relies are issued to external professionals, and if the Group were to end its business relationship with such persons, it may face temporary disruptions to operations while engaging other service providers. The Group's services heavily rely to some extent on medical equipment such as X-ray machines, and the rental, replacement, upgrading, or maintenance of such equipment can incur substantial costs. The Group's information technology systems assist in managing clinical systems, medical records, and inventory, and technical failures stemming from issues like power failures, computer viruses, or unauthorized tampering may disrupt the Group's ability to provide services to patients.

The Group incurs significant legal, accounting and other expenses as a public company that it did not incur as a private company. The Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the Securities and Exchange Commission and Nasdaq impose various requirements on corporate governance practices of public companies. As a company with less than US$1.235 billion in net revenues for its last financial year, the Group qualifies as an emerging growth company pursuant to the JOBS Act, and may take advantage of specified reduced reporting and other requirements, including exemption from the auditor attestation requirement under Section 404 of the Sarbanes-Oxley Act of 2002 and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies. The Group expects these rules and regulations to increase legal and financial compliance costs and to make some corporate activities more time-consuming and costly.

The Group faces structural headwinds including the highly dilutive nature of the October 2026 Offering, which may cause Nasdaq to halt trading in the Ordinary Shares or delist the Ordinary Shares for public interest concerns or because the Ordinary Shares trade below Nasdaq's minimum bid price of US$1.00. The common warrants issued in the October 2026 Offering are exercisable immediately at an exercise price equal to 110% of the public offering price per unit and expire five years from issuance, and holders may exercise them by means of a zero cash exercise price option, under which they would receive the same number of Ordinary Shares issuable upon a cash exercise without paying any additional consideration. As a result, the Group does not expect to receive any additional funds upon exercise of the common warrants, and the issuance of up to 6,000,000 additional Ordinary Shares upon such exercise would substantially dilute existing shareholders.

The Group faces constraints from the regulatory environment in Singapore, including regulations from the Ministry of Health, Health Sciences Authority, Ministry of Manpower, and the Singapore Medical Council. These regulations encompass aspects such as the pricing of medical services, procurement of medical equipment, licensing and operation of medical establishments, and licensing of medical staff. Singapore's stringent safety, health, and environmental laws could become stricter in the future, and violations of these regulatory requirements may lead to fines, operational modifications, suspensions, or discontinuation, incurring additional operating costs, and potential criminal charges against employees. Changes in government regulations or the introduction of new laws may increase compliance costs, and authorities like the MOH and SMC could suspend or deny the renewal of existing licenses if the Group fails to meet applicable standards.

Management's message to shareholders emphasizes the Group's position as a specialist healthcare provider in Singapore focused on orthopedic, trauma, sports medicine and neurosurgical services, health screening and general practice, with a strategy centered on expanding its clinic network and service offerings. The Group completed the acquisition of Bethesda Medical Pte. Ltd. effective April 30, 2025, adding multiple clinic locations, and completed its initial public offering in February 2025 with an over-allotment option exercised in March 2025. Management highlights the Group's compliance with the Ministry of Health's Fee Benchmarks, with all services presently priced within the benchmarks. The Group's strategic priorities include recruiting and retaining sufficiently skilled and qualified medical practitioners to support operations and continued expansion, maintaining key relationships with corporations that account for a significant portion of patient volume, and managing operating costs including lease rental rates and risk of relocation. Management acknowledges the Group has in the past defaulted on certain terms stipulated under loan agreements with banks, and that further events of default could cause all amounts outstanding with respect to that debt to be due and payable immediately. The Group effected a 1-for-12 reverse share split on June 22, 2026, resulting in 1,582,111 ordinary shares outstanding as of June 30, 2026, and on October 7, 2026, issued and sold 6,000,000 units at a public offering price of US$1.33 per unit, resulting in 7,582,111 Ordinary Shares issued and outstanding immediately after the October 2026 Offering.

The Group's financial performance for the fiscal year ended June 30, 2026 reflects its operations as a specialist healthcare provider in Singapore. Revenue is derived from medical services, with revenue recognized at a point in time as services are transferred. The Group's borrowings include term loans, lease liabilities, short-term borrowings and bank overdrafts, with the Group having entered into certain loan agreements with certain banks to fund working capital requirements. The Group completed the acquisition of Bethesda Medical Pte. Ltd. effective April 30, 2025, with the acquisition accounting reflecting a business combination. The Group effected a 1-for-12 reverse share split on June 22, 2026, resulting in 1,582,111 ordinary shares outstanding as of June 30, 2026. On October 7, 2026, the Group issued and sold 6,000,000 units at a public offering price of US$1.33 per unit, each unit consisting of one Ordinary Share (or one pre-funded warrant to purchase one Ordinary Share) and one common warrant to purchase one Ordinary Share, with each common warrant exercisable immediately at an exercise price equal to 110% of the public offering price per unit and expiring five years from issuance. Immediately after the October 2026 Offering, the Group had 7,582,111 Ordinary Shares issued and outstanding. The Group qualifies as an emerging growth company with less than US$1.235 billion in net revenues for its last financial year. The Group's property, plant and equipment include machinery, fixtures and fittings, medical equipment, renovation, air conditioner, computer and office equipment, and software, with depreciation and amortization recognized on these assets. The Group's financial assets are categorized into different levels for fair value measurement, and the Group has financial assets at fair value through profit or loss. The Group's trade receivables are subject to credit risk, with allowances for credit losses recognized based on expected credit losses. The Group's lease liabilities are recognized in accordance with IFRS 16, and the Group has short-term borrowings and bank overdrafts. The Group's related party transactions include transactions with related parties, and the Group has a non-controlling interest. The Group's equity includes issued capital, merger reserve, reserve of exchange differences on translation, retained earnings, equity attributable to owners of parent, and non-controlling interests.

The Group faces material risks specific to its business and financial position. The Group has in the past defaulted on certain terms stipulated under loan agreements with banks, and if there were further events of default, the lender could cause all amounts outstanding with respect to that debt to be due and payable immediately, and the Group's assets or cash flow may not be sufficient to fully repay borrowing under such loans if accelerated upon an event of default. The Group is dependent on a number of key relationships with corporations for a significant portion of its patient volume, and the loss of one or more of these key relationships or reduced demand for managed healthcare solutions could have a material adverse effect on patient volume. The Group is exposed to credit risks of customers, especially corporate clients which tend to incur larger transaction volumes compared to individual patients, and failure to collect trade receivables fully or promptly may require full or partial allowances for impairment or write off bad debts. The Group's present lease terms for most clinics are for a period of three years or less, and upon expiry, landlords have the right to review and revise the terms and conditions, with any increase in rent inevitably increasing operating costs and affecting profits. The Group's services are priced within the Ministry of Health's Fee Benchmarks, and if the Fee Benchmarks are lowered, the Group may need to adjust fees accordingly, potentially reducing revenues and profitability. The Group's common warrants issued in the October 2026 Offering are exercisable immediately at an exercise price equal to 110% of the public offering price per unit and expire five years from issuance, and holders may exercise them by means of a zero cash exercise price option, resulting in the issuance of up to 6,000,000 additional Ordinary Shares and substantial dilution to existing shareholders.